mol **Financial Services**

Estimate change	
TP change	
Rating change	$ \longleftarrow $

Bloomberg	SYRMA IN
Equity Shares (m)	178
M.Cap.(INRb)/(USDb)	93.7 / 1.1
52-Week Range (INR)	647 / 355
1, 6, 12 Rel. Per (%)	2/-9/21
12M Avg Val (INR M)	694

Financials & Valuations (INR b)

		,	
Y/E Mar	FY25	FY26E	FY27E
Sales	37.9	51.1	66.4
EBITDA	3.0	4.1	5.4
Adj. PAT	1.7	2.6	3.7
EBITDA Margin (%)	8.0	8.0	8.2
Cons. Adj. EPS (INR)	9.7	14.6	20.7
EPS Gr. (%)	57.6	50.9	41.9
BV/Sh. (INR)	98.3	111.4	130.5
Ratios			
Net D:E	0.2	0.2	0.1
RoE (%)	10.2	13.9	17.1
RoCE (%)	10.2	12.9	15.9
Valuations			
P/E (x)	54	36	25
EV/EBITDA (x)	32	24	18

Shareholding Pattern (%)

As on	Mar-25	Dec-24	Mar-24			
Promoter	46.5	46.6	46.9			
DII	7.7	7.5	5.8			
FII	6.3	8.6	13.0			
Others	39.5	37.4	34.4			
Note: Ell includes depository receipts						

Note: FII includes depository receipts

CMP: INR526

TP: INR630 (+20%)

Syrma SGS Technology

Buy

Changing business mix underpins margin expansion

Operating performance in line

- Syrma SGS Technology (SYRMA) reported a strong operating performance in 4QFY25, with EBITDA rising ~46% YoY and margins expanding 510bp YoY, fueled by a favorable business mix (share of low-margin consumer business at 21% in 4QFY25 vs. 46% in 4QFY24). Revenue dipped 19% YoY, mainly due to a 64%/20% YoY decline in consumer/healthcare businesses.
- With the order book continuing to improve to over INR53b as of 4QFY25 (up 19% YoY) and margins expanding, we expect SYRMA to witness a stronger FY26 performance. Management guided 30-35% revenue growth and ~8% EBITDA margin for FY26.
- We broadly maintain our FY26/FY27 EPS estimates and reiterate our BUY rating on the stock with a TP of INR630 (premised on 30x FY27E EPS).

Growth in Automotive and Industrial aids margin expansion

- Consol. revenue declined 19% YoY to INR9.2b (est. INR13.6b) owing to a decline in consumer/healthcare business by 64%/28% YoY. This was offset by a 19%/44%/12% YoY increase in Automotive/industrial /IT & Railway businesses.
- EBITDA margin expanded 510bp YoY to 11.6% (est. 7.7%), which can be attributed to the gross margin expansion of 1,000bp YoY to 27.2%, led by a favorable business mix (lower share of high-volume, low-margin business). EBITDA jumped 46% YoY to INR1b (in line). Adj. PAT surged 87% YoY to INR654m (in line).
- The order book was over INR53b as of Mar'25 vs. INR45b as of Mar'24. The consumer, industrial, automotive, healthcare, and IT & railways segments accounted for ~30%, 28-30%, 25-30%, and the remaining portion of total orders as of Mar'25.
- In FY25, SYRMA's revenue/EBITDA/Adj. PAT grew 20%/52%/58% YoY to INR38b/INR3b/INR1.7b. CFO for FY25 stood at INR1.7b as against a negative CFO of INR1.1b in FY24. Net WC days declined from 70 days in FY24 to 69 days in FY25. The management expects to sustain WC days around these levels going ahead.
- Gross debt mounted to ~INR6.1b as of Mar'25 from INR5.7b as of Mar'24. Net debt was ~INR2.6b as of Mar'25 vs. INR1.7b as of Mar'24.

Highlights from the management commentary

Guidance: Management expects an EBITDA margin of ~8% in FY26, translating into INR4b in absolute terms. Strategically, management would like to reduce its exposure to low-margin, high-volume business. Even in the consumer business, the company would continue to grow its high-margin ODM segment.

Research Analyst: Sumant Kumar (Sumant.Kumar@MotilalOswal.com) | Meet Jain (Meet.Jain@MotilalOswal.com)

Research Analyst: Nirvik Saini (Nirvik.Saini @MotilalOswal.com) | Yash Darak (Yash.Darak@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report. Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.



- Exports remained subdued in FY25 due to tariff-related uncertainties, but the company is confident of crossing the INR10b export mark in FY26. Export growth will also be supported by new clients onboarded in the last 4-5 months, alongside a gradual recovery in EU demand and contributions from the healthcare vertical.
- Healthcare: SYRMA is witnessing traction in sub-segments such as neonatal care, respiratory and heart monitoring devices, and cosmetic lasers. According to the management, these products build long-term growth visibility, since design-led engagements often translate into commercial production 2-3 years later.

Valuation and view

- SYRMA continued its margin recovery, driven by a favorable shift in the business mix in 4Q/FY25. We expect its margins to expand in FY26 as well, led by a decline in the mix of consumer business (lower share in the closing order book).
- We believe that the company's long-term trajectory will continue to be strong, backed by: 1) its focus on low-volume, high-margin business; 2) an increase in exports; 3) the addition of new customers in the industrial and automotive segments; and 4) increasing traction in the healthcare business going forward.
- We estimate a revenue/EBITDA/adj. PAT CAGR of 32%/34%/46% over FY25-27, driven by strong revenue growth and margin expansion. We reiterate our BUY rating on the stock with a TP of INR630 (premised on 30x FY27E EPS).

Consolidated - Quarterly Earnings Model (INR							(INR m)					
Y/E March		FY2	24			FY2	25		FY24	FY25	FY25E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4QE	%
Gross Sales	6,013	7,117	7,067	11,341	11,599	8,327	8,692	9,244	31,538	37,862	13,609	-32
YoY Change (%)	54.4	52.4	37.9	66.9	92.9	17.0	23.0	-18.5	54.0	20.1	20.0	
Total Expenditure	5,644	6,627	6,679	10,604	11,153	7,618	7,901	8,169	29,554	34,841	12,557	
EBITDA	369	490	388	737	446	710	791	1,075	1,984	3,021	1,051	2
Margins (%)	6.1	6.9	5.5	6.5	3.8	8.5	9.1	11.6	6.3	8.0	7.7	
Depreciation	101	116	139	158	174	167	202	208	515	751	210	
Interest	75	80	100	123	130	136	154	156	378	577	120	
Other Income	221	89	121	156	153	100	223	223	587	699	177	
PBT before EO expense	413	383	270	612	295	507	657	934	1,678	2,392	898	
Extra-Ord expense	0	14	0	0	0	0	21	0	14	21	0	
РВТ	413	370	270	612	295	507	635	934	1,664	2,371	898	
Тах	130	64	67	160	91	110	105	219	421	526	226	
Rate (%)	31.5	17.4	24.8	26.1	31.0	21.8	16.6	23.5	25.3	22.2	25.2	
MI & Profit/Loss of Asso. Cos.	-2	22	48	103	10	34	42	60	170	147	35	
Reported PAT	285	283	155	349	193	362	488	654	1,073	1,698	637	
Adj PAT	285	297	155	349	193	362	50 9	654	1,087	1,719	637	3
YoY Change (%)	84.0	4.8	-53.2	-17.4	-32.3	22.0	228.2	87.3	-8.9	58.2	82.3	
Margins (%)	4.7	4.2	2.2	3.1	1.7	4.4	5.9	7.1	3.4	4.5	4.7	

Consolidated - Quarterly Farnings Model



Key exhibits




Exhibit 3: Consolidated Adj. PAT trend





Exhibit 4: End-user industry mix

Auto	Cor	sumer	Hea	lthcare	e 🔳 Ind	ustrial	■ IT &	railwa	ays
-5%		7%		5%		6%		5%	
23%		19% 5%		29%		31%		41%	
10%		5%		8%		8%		41/0	
4.00/		53%		33%		31%		10%	
46%		00/0		5570		31%		21%	
16%		16%		25%		24%		23%	
 -									
Y24		Y25		Y25		Y25		Y25	
4QFY24		QFY25		2QFY25		3QFY25		4QFY25	
 4		Ч		2		ŝ		4	

Exhibit 5: Closing order book trend

Order book (INR b)

Exhibit 6: Revenue growth YoY across end-user verticals







Highlights from the management commentary

Operating performance

- Margin expansion was largely driven by a favorable change in the product mix, along with initiatives implemented by management, which have started to yield results.
- As of Mar'25, net working capital stood at 69 days. Inventory levels have been brought down by 18% to INR8.2b, down from INR1b+ in FY24.
- Gross debt as of Mar'25 stood at ~INR6.1b

Outlook and guidance

- Going forward, the company expects ~30% of revenue to come from the consumer business.
- The company expects EBITDA margins of approximately 8% in FY26, translating to INR4b in absolute terms. The company will reassess its margin guidance as the year progresses.
- Management expects the company to grow at the rate of ~30-35%, with a continued focus on margin expansions.
- The export business is expected to surpass INR10b for FY26. The jump in export revenue will be aided by new customers, which could contribute for only five months in FY25.
- The company's focus shall be on high-margin growth driver businesses as opposed to volume accretive businesses.
- The company added 25-30 new customers in FY26, 3/4th of which may be in the automotive and industrial business.

Order book

- As of Mar'25, the order book stood at >INR53b. Execution timeline for the order book varies, with some extending up to 18 months.
- The auto/consumer/industrial mix of the order book stands at 25-30%/30%/28-30%.
- Some customers provide orders for the whole year, while some of them provide short-term orders. Hence, order visibility varies from customer to customer.

Industrial Business

- Key growth drivers include energy metering for domestic markets and utility metering/power supplies for international clients.
- Smart meters form a significant share: ~4m units delivered in FY25, contributing over INR3b in revenue; robust growth is expected to continue.
- Client acquisition in the smart metering segment remains strategic and selective.

Consumer Business

- Strategically, the company aims to reduce exposure to low-margin, high-volume consumer products while continuing to grow the high-margin ODM segment.
- RFID currently contributes ~8% of revenues, expected to rise to 8–10% in FY26
- Only low-margin consumer products will be scaled down.



Capex

- The company incurred a capex of ~INR1.80b in FY25, which was largely spent towards the Pune facility.
- The company attained an asset turnover of 5.5x during FY25
- SYRMA may continue to invest in capex as it may deem fit; it is expanding its Bangalore facility currently to serve its increasing business there

Others

- The company booked PLI incentives of INR350-360m/INR80m for FY25/Q4FY25. PLI-related income of INR150-180m is expected in FY26.
- High-margin businesses have an elongated WC cycle, however, the company may be able to maintain and even reduce the same going forward.
- There is a lot of volatility in the tariff environment, but India may not be affected negatively due to tariffs.
- QIP may be used for inorganic acquisition or to enter into the component manufacturing scheme. The proper allocation of the same has not been decided yet.
- EcoVadis, which is a global agency that monitors ESG, has given a percentile score of plus 70%, and the company is among the top 35 companies globally that are meeting the ESG norms set by the companies and the government.
- Core growth drivers going ahead may be automotive, industrial, and exports

Valuation and view

- SYRMA continued its margin recovery, driven by a favorable shift in the business mix in 4Q/FY25. We expect its margins to expand in FY26 as well, led by a decline in the mix of consumer business (lower share in the closing order book).
- We believe that the company's long-term trajectory will continue to be strong, backed by: 1) its focus on low-volume, high-margin business; 2) an increase in exports; 3) the addition of new customers in the industrial and automotive segments; and 4) increasing traction in the healthcare business going forward.
- We estimate a revenue/EBITDA/adj. PAT CAGR of 32%/34%/46% over FY25-27, driven by strong revenue growth and margin expansion. We reiterate our BUY rating on the stock with a TP of INR630 (premised on 30x FY27E EPS).

Earnings change	Old		Ne	ew	Change		
(INR m)	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E	
Revenue	57,007	74,109	51,113	66,447	-10%	-10%	
EBITDA	4,218	5,632	4,089	5,449	-3%	-3%	
Adj. PAT	2,712	3,795	2,594	3,681	-4%	-3%	

Exhibit 7: Changes to our estimates

Financial Services

m

Financials and valuations

Consolidated - Income Statement	EV/20	EV24	EV22	EVOD	EV24	EVOE	EVACE	(INR m)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Total Income from Operations	8,621	8,858	12,667	20,484	31,538	37,862	51,113	66,447
Change (%)	143.5	2.8	43.0	61.7	54.0	20.1	35.0	30.0
RM Cost	5,847	6,276	9,408	15,405	25,069	29,258	39,511	51,430
Employees Cost	748	781	823	1,060	1,426	1,887	2,505	3,057
Other Expenses	731	786	1,148	2,142	3,059	3,696	5,009	6,512
Total Expenditure	7,325	7,842	11,380	18,606	29,554	34,841	47,024	60,999
% of Sales	85.0	88.5	89.8	90.8	93.7	92.0	92.0	91.8
EBITDA	1,295	1,016	1,287	1,878	1,984	3,021	4,089	5,449
Margin (%)	15.0	11.5	10.2	9.2	6.3	8.0	8.0	8.2
Depreciation	191	228	249	312	515	751	790	803
EBIT	1,105	789	1,038	1,566	1,469	2,270	3,299	4,646
Int. and Finance Charges	154	97	108	216	378	577	478	380
Other Income	183	177	178	437	587	699	920	997
PBT bef. EO Exp.	1,134	869	1,108	1,787	1,678	2,392	3,741	5,263
EO Items	0	0	0	0	-14	-21	0	0
PBT after EO Exp.	1,134	869	1,108	1,787	1,664	2,371	3,741	5,263
Total Tax	219	213	343	556	421	526	942	1,325
Tax Rate (%)	19.3	24.5	31.0	31.1	25.3	22.2	25.2	25.2
Minority Interest	31	25	42	38	170	147	206	257
Reported PAT	884	630	722	1,193	1,073	1,698	2,594	3,681
Adjusted PAT	884	630	722	1,193	1,087	1,719	2,594	3,681
Change (%)	321.5	-28.7	14.5	65.2	-8.9	58.2	50.9	41.9
Margin (%)	10.3	7.1	5.7	5.8	3.4	4.5	5.1	5.5

Consolidated - Balance Sheet

consonatica Balance Sheet								
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	46	46	1,376	1,768	1,774	1,780	1,780	1,780
Preference Capital	47	0	0	0	0	0	0	0
Total Reserves	4,182	5,946	4,344	13,635	14,352	15,719	18,046	21,460
Net Worth	4,275	5,992	5,721	15,403	16,126	17,500	19,826	23,240
Minority Interest	2	6	108	26	644	749	954	1,211
Total Loans	1,205	1,029	2,183	3,468	5,763	6,112	5,412	4,712
Deferred Tax Liabilities	42	62	124	138	176	139	139	139
Capital Employed	5,523	7,089	8,136	19 ,035	22,710	24,499	26,331	29,303
Gross Block	2,089	2,264	3,233	4,821	8,134	9,077	9,964	10,882
Less: Accum. Deprn.	191	405	635	947	1,462	2,213	3,003	3,805
Net Fixed Assets	1,898	1,858	2,597	3,874	6,672	6,864	6,961	7,076
Goodwill on Consolidation	1,059	1,059	1,182	1,182	3,221	3,221	3,221	3,221
Capital WIP	12	0	408	253	168	609	522	604
Total Investments	301	1,316	410	8,500	419	594	594	594
Current Investments	0	0	0	780	355	514	514	514
Curr. Assets, Loans&Adv.	4,591	5,365	6,945	11,603	26,414	30,758	38,722	48,603
Inventory	1,419	1,789	2,913	5,874	10,043	8,219	11,203	14,564
Account Receivables	1,804	2,084	2,722	4,032	9,301	14,775	19,605	25,487
Cash and Bank Balance	780	729	369	544	856	2,958	1,781	1,243
Loans and Advances	588	763	940	1,151	6,215	4,807	6,134	7,309
Curr. Liability & Prov.	2,338	2,509	3,407	6,377	14,185	17,548	23,689	30,796
Account Payables	1,707	1,848	2,405	4,881	12,232	15,744	21,254	27,630
Other Current Liabilities	506	554	857	1,362	1,778	1,597	2,156	2,803
Provisions	125	108	145	134	174	207	279	362
Net Current Assets	2,253	2,856	3,538	5,226	12,230	13,211	15,033	17,807
Misc Expenditure	0	0	0	0	0	0	0	0
Appl. of Funds	5,523	7,089	8,136	19,035	22,710	24,499	26,331	29,303
			-		-	-		-



Financials and valuations

Ratios								
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Basic (INR)								
EPS	6.4	4.6	5.2	6.7	6.1	9.7	14.6	20.7
Cash EPS	7.8	6.2	7.1	8.5	9.0	13.9	19.0	25.2
BV/Share	31.1	43.5	41.6	87.1	90.9	98.3	111.4	130.5
DPS	0.0	0.0	0.0	0.0	1.5	1.5	1.5	1.5
Payout (%)	0.0	0.0	0.0	0.0	24.8	15.7	10.3	7.3
Valuation (x)								
P/E	81.9	114.8	100.3	77.9	85.9	54.5	36.1	25.4
Cash P/E	67.4	84.4	74.5	61.8	58.3	37.9	27.7	20.9
P/BV	16.9	12.1	12.7	6.0	5.8	5.4	4.7	4.0
EV/Sales	8.4	8.2	5.9	4.6	3.1	2.6	1.9	1.5
EV/EBITDA	56.2	71.5	57.7	50.7	49.7	32.1	23.9	18.0
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.3	0.3	0.3	0.3
FCF per share	7.8	1.3	-7.5	-12.1	-25.4	0.2	-3.7	-1.1
Return Ratios (%)								
RoE	35.8	12.3	12.3	11.3	6.9	10.2	13.9	17.1
RoCE	29.4	11.7	11.2	10.3	7.5	10.2	12.9	15.9
RoIC	31.1	12.6	11.9	12.9	7.1	8.5	11.3	13.8
Working Capital Ratios		-	-	-				
Fixed Asset Turnover (x)	4.1	3.9	3.9	4.2	3.9	4.2	5.1	6.1
Asset Turnover (x)	1.6	1.2	1.6	1.1	1.4	1.5	1.9	2.3
Inventory (Days)	60	74	84	105	116	79	80	80
Debtor (Days)	76	86	78	72	108	142	140	140
Creditor (Days)	70	76	69	87	142	152	152	152
Leverage Ratio (x)	72	70	05	0,	172	152	152	152
Current Ratio	2.0	2.1	2.0	1.8	1.9	1.8	1.6	1.6
Interest Cover Ratio	7.2	8.1	9.6	7.3	3.9	3.9	6.9	12.2
Net Debt/Equity	0.1	0.1	0.3	0.1	0.3	0.2	0.2	0.1
	0.1	0.1	0.5	0.1	0.5	0.2	0.2	0.1
Consolidated - Cash Flow Statement								(INR m)
	EV20	EV.24	EV22	51/22	51/2.4	EV/2E	EVOCE	
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
OP/(Loss) before Tax	1,134	869	1,108	1,787	1,664	2,371	3,741	5,263
Depreciation	191	228	249	312	515	751	790	803
Interest & Finance Charges	117	52	54	-222	378	585	-442	-617
Direct Taxes Paid	-207	-220	-289	-556	-540	-607	-942	-1,325
(Inc)/Dec in WC	301	-499	-1,212	-2,140	-2,804	-934	-3,000	-3,311
CF from Operations	1,535	430	-90	-818	-786	2,165	148	813
Others	23	-58	-36	115	-350	-400	0	0
CF from Operating incl EO	1,558	371	-126	-703	-1,136	1,765	148	813
(Inc)/Dec in FA	-479	-187	-901	-1,433	-3,370	-1,726	-800	-1,000
Free Cash Flow	1,079	184	-1,027	-2,136	-4,506	39	-652	-187
(Pur)/Sale of Investments	-20	-51	11	0	-2,300	605	0	0
Others	42	-888	-2,844	-7,711	5,388	69	920	997
CF from Investments	-457	-1,127	-3,734	-9,144	-282	-1,052	120	-3
Issue of Shares	0	331	2,715	9,682	0	0	0	0
Inc/(Dec) in Debt	-416	-179	1,159	1,285	2,295	330	-700	-700
Interest Paid	-119	-70	-70	-216	-378	0	-478	-380
Dividend Paid	-20	0	0	0	0	-266	-267	-267
Others	-37	622	-303	-730	-187	1,326	0	0
CF from Fin. Activity	-593	705	3,500	10,022	1,730	1,389	-1,445	-1,347
Inc/Dec of Cash	508	-51	-360	175	312	2,102	-1,177	-537
Opening Balance	143	780	729	369	544	856	2,958	1,781
Other cash & cash equivalent	120	0	0	0				

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

0

729

0

369

0

856

2,958

1,781

544

130

780

Other cash & cash equivalent

Closing Balance

1,243



NOTES

a flags of the sector and Deffe

Explanation of investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation
*In case the recommendation given by the Dessereb Analys	tic inconsistant with the investment rating legand for a continuous paried of 20 days, the Desparah Analyst shall be within followin

In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at ports.motilaloswal.com/Dormant/documents/List%20 ciate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at val.com/ResearchAnalyst/PublishViewLitigation.as

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong. For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com Contact: (+65) 8328 0276

Specific Disclosures

Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). 1 MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes. Nature of Financial interest is holding equity shares or derivatives of the subject company

2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.

MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No

3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.

- MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- 4 Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies). 5
- 6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months. 7.



- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) 8. in the past 12 months.
- 9 MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- 10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOESL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. **Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Savani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085. al Cell:

Grievance	Redressa

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities .: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.